Increased level of C3 in synovial fluid in patients with activated osteoarthritis as a diagnostic and therapeutic target – pilot group of patients from the Rheumatology Department at UMHAT Burgas
Vol. 31 No. 3 (2023), Original Articles
Vol. 31 No. 3 (2023)

Increased level of C3 in synovial fluid in patients with activated osteoarthritis as a diagnostic and therapeutic target – pilot group of patients from the Rheumatology Department at UMHAT Burgas

Original Articles
https://doi.org/10.35465/31.3.2023.pp19-29
Published December 12, 2023
Irina Ivanova Momcheva
Ревматология
https://orcid.org/0000-0002-7801-2007
PDF EN
PDF BG (Български)

Keywords

osteoarthritis
complement fractions
innate immune response
low-grade inflammation

How to Cite

Momcheva, I. (2023). Increased level of C3 in synovial fluid in patients with activated osteoarthritis as a diagnostic and therapeutic target – pilot group of patients from the Rheumatology Department at UMHAT Burgas. Rheumatology (Bulgaria), 31(3), 19-29. https://doi.org/10.35465/31.3.2023.pp19-29
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

The clinical course of osteoarthritis (OA) indicates the role of low-grade synovitis as the main driver of the degenerative process. Components of the extracellular matrix, fibronectin isoforms, and fragments of hyaluronic acid are presumed ligands for DAMPs (particularly TLR). Complement fractions bind to the corresponding receptors on the cell membranes of chondrocytes and synoviocytes through TLR. Does the complement cascade play a role only as a clearing system and/or a leading pathogenetic factor in activated OA? The aim of this study is to answer this question. The study included 50 patients with activated OA of the knee joint. We examined the levels of C3 and C4 complement fractions in the blood plasma and synovial fluid. We found that the values of these proteins in synovial fluid were on average 34.90% for C3 and 30.97% for C4 of their values in blood plasma, with a generally accepted norm of 10% for complement levels in a healthy joint. The observation regarding the strength of correlation between the above results and the radiological stage confirmed a stronger correlation of the obtained results in the earlier stages of the disease when the activity of the repair processes is more pronounced. In this way, we objectified the pathogenetic role of complement in the arthritic process, as well as its role in clearing the joint space from degradation products. The question arises whether pharmacological intervention to balance complement activation could represent a future therapeutic strategy in the treatment of OA and prevent its progression.

https://doi.org/10.35465/31.3.2023.pp19-29
PDF EN
PDF BG (Български)

References

  1. Mobasheri A, Kapoor M, Amanda Ali S, et al. The future of deep phenotyping in osteoarthritis: How can high throughput omics technologies advance our understanding of the cellular and molecular taxonomy of the disease? Osteoarthritis Cartilage. 2021;3:100144. doi: 10.1016/j.ocarto.2021.100144
  2. Kraus VB, Blanco FJ, Englund M, et al. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthritis Cartilage. 2015;23(8):1233-41. doi: 10.1016/j.joca.2015.03.036
  3. Johannes WJ Bijlsma, G. Burmester, J. Silva, et al. EULAR Compendium on Rheumatic Diseases, р. 444-450.
  4. Knevel R., Schoels M., Huizinga T., Aletaha D., Burmester G., Combe B., et al. (2010) Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69: 987–994
  5. Ospelt C, Brentano F, Rengel Y, Stanczyk J, Kolling C, Tak PP, Gay RE, Gay S, Kyburz D.Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum. 2008; 58:3684–92.
  6. Ozawa T, Koyama K, Ando T, Ohnuma Y, Hatsushika K, Ohba T, Sugiyama H, Hamada Y, Ogawa H, Okumura K, Nakao A. Thymic stromal lymphopoietin secretion of synovial fibroblasts is positively and negatively regulated by Toll-like receptors/nuclear factor-kappaB pathway and interferon-gamma/dexamethasone. Mod Rheumatol. 2007; 17:459–63.
  7. . Tamaki Y, Takakubo Y, Hirayama T, Konttinen YT, Goodman SB, Yamakawa M, Takagi M. Expression of Toll-like receptors and their signaling pathways in rheumatoid synovitis. J Rheumatol. 2011; 38:810–20.
  8. Xutao Xi, Arshad Mehmood, Pengyan Niu, Jinjie Yang, Yintian Wang, Heyu Zhou, Xiaohui Han, Lifen Ma, Shiying Jin, Association of X-linked TLR-7 gene polymorphism with the risk of knee osteoarthritis: a case–control study, Scientific reports, 12, Article number: 7243 (2022)
  9. Sellam J., Berenbaum F. (2010) The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis Nat Rev. Rheumatol 2010 Nov;6(11):625-35. doi: 10.1038/nrrheum.2010.159.Epub 2010 Oct 5.
  10. ShineB., J T Bourne, F Begum Baig, J Dacre, and D V Doyle, C reactive protein and immunoglobulin G in synovial fluid and serum in joint disease., Journal List Ann Rheum Dis v.50(1); 1991 Jan PMC1004321 50(1): 32–35
  11. Hochberg M., Silman A., Smolen J., Weinblatt M., Weisman M. Rheumatology, sixth edition, 2015, p.237-241
  12. Kawai T., Akira S. (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors; 2010 May;11(5):373-84. doi: 10.1038/ni.1863. Epub 2010 Apr 20.
  13. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010 2010.
  14. Ishijima M, Watari T, Naito K, Kaneko H, Futami I, Yoshimura-Ishida K, Tomonaga A, Yamaguchi H, Yamamoto T, Nagaoka I, Kurosawa H, Poole RA, Kaneko K. Relationships between biomarkers of cartilage, bone, synovial metabolism and knee pain provide insights into the origins of pain in early knee osteoarthritis. Arthritis Res Ther. 2011; 13:R22.
  15. Janeway CA Jr. Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002; 20:197–216.
  16. Kawai T., Akira S. (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors, Nat Immunol 11: 2010 May;11(5):373-84. doi: 10.1038/ni.1863. Epub 2010 Apr 20
  17. Ospelt C, Brentano F, Rengel Y, Stanczyk J, Kolling C, Tak PP, Gay RE, Gay S, Kyburz D.Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum. 2008; 58:3684–92.
  18. Ozawa T, Koyama K, Ando T, Ohnuma Y, Hatsushika K, Ohba T, Sugiyama H, Hamada Y, Ogawa H, Okumura K, Nakao A. Thymic stromal lymphopoietin secretion of synovial fibroblasts is positively and negatively regulated by Toll-like receptors/nuclear factor-kappaB pathway and interferon-gamma/dexamethasone. Mod Rheumatol. 2007; 17:459–63.
  19. Kuy immunology. Macmillian, 2007. ISBN978-1-4292-0211-4.c.299; Abbas AK,LichmanAH,Pillai S. Cellular and Mollecular Immunology..6th.Elsevier2010. ISBN978-1-4160-3123-9.
  20. Goldman AS, Prabhakar BS. The Complement System. in: Baron's Medical Microbiology (Baron S et al., eds.). 4th. Univ of Texas Medical Branch, 1996. ISBN 0-9631172-1-1.
  21. Okumura N, Nomura M, Tada T. Effects of sample storage on serum c3c assay by nephelometry. Clinical Laboratory Science. 1990;3:54–57. [Google Scholar]
  22. Garred P, Mollnes TE, Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scandinavian Journal of Immunology. 1988;27(3):329–335.
  23. Wang Q., Rozelle A., Lepus С., Scanzello С., Song J., Larsen D., et al. (2011) Identification of a central role for complement in osteoarthritis. Nat Med 17: 1674-1679
  24. Wei Lu, Lin Wang, Jing Yao, Chunxin Wo, Yu Chen C5a aggravates dysfunction of the articular cartilage and synovial fluid in rats with knee joint immobilization, Published online on: June 22, 2018, Pages: 2110-2116
  25. Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology..6th. Elsevier, 2010.
  26. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785–97.
  27. Happonen KE, Heinegård D, Saxne T, Blom AM. Interactions of the complement system with molecules of extracellular matrix: relevance for joint diseases. Immunobiology. 2012;217(11):1088–96.
  28. Happonen KE, Saxne T, Aspberg A, Mörgelin M, Heinegård D, Blom AM. Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum. 2010;62(12):3574–83.
  29. Melin Fürst C, Mörgelin M, Vadstrup K, Heinegård D, Aspberg A, Blom AM. The C-type lectin of the aggrecan G3 domain activates complement. PLoS One. 2013;8(4):e61407.
  30. Sjöberg A, Onnerfjord P, Mörgelin M, Heinegård D, Blom AM. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J Biol Chem. 2005;280(37):32301–8.].
  31. Okamura Y., Watari M., Jerud E., Young D., Ishizaka S., Rose J., et al. (2001) The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276: 10229–10233
  32. Termeer C., Benedix F., Sleeman J., Fieber C., Voith U., Ahrens T., et al. (2002) Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 195: 99–111
  33. Neumann E, Barnum SR, Tarner IH, Echols J, Fleck M, Judex M, et al. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 2002; 46: 934-945.
  34. Guc D, Gulati P, Lemercier C, Lappin D, Birnie GD, Whaley K. Expression of the components and regulatory proteins of the alternative complement pathway and the membrane attack complex in normal and diseased synovium. Rheumatol Int. 1993; 13: 139-146.
  35. King Strasinger S et al. (2008): Urinalysis and Body Fluids. Fifth Edition. © 2008 F. A. Davis Co.
  36. Thomas L, Labor and Diagnose, 5th ed. Frankfurt& 1998; 812-823.
  37. Tietz NW, Clinical Guide to Laboratoty Tests, 3th ed.1995; 164-165.
  38. E Mollnes, P Garred, and G BergsethEffect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol. 1988 Sep; 73(3): 484–488.
  39. Very viscous fluids may need to be pre-treated for further analysis by adding 400 units of the enzyme hyaluronidase to 1 mL of fluid and incubating the mixture at 37 °C for 10 minutes [Clinical and Laboratory Standards Institute (2006): Body Fluid Analysis for Cellular Composition. Approved Guideline. CLSI document H56-A [ISBN: 1-56238-614-X].
  40. Raynauld J., Martel-Pelletier J., Bias P., Laufer S., Haraoui B., Choquette D., et al. (2009) Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis 68: 938–947
  41. Brandt K., Mazzuca S., Katz B., Lane K., Buckwalter K., Yocum D., et al. (2005) Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 52: 2015–2025
  42. Hunter D. (2008) Are there promising biologic therapies for osteoarthritis? Curr Rheumatol Rep 10: 19–25
  43. Ru Liu-Bryan, Curr Rheumatol Rep. Synovium and the Innate Inflammatory Network in Osteoarthritis Progression.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.